Potential and clinical utility of stem cells in cardiovascular disease

Korff Krause
Carsten Schneider
Kai Jaquet
Karl-Heinz Kuck
Hanseatic Heart Center Hamburg, Department of Cardiology, Asklepios Hospital St. Georg, Hamburg, Germany

Abstract: The recent identification of bone marrow-derived adult stem cells and other types of stem cells that could improve heart function after transplantation have raised high expectations. The basic mechanisms have been studied mostly in murine models. However, these experiments revealed controversial results on transdifferentiation vs transfusion of adult stem cells vs paracrine effects of these cells, which is still being debated. Moreover, the reproducibility of these results in precisely translated large animal models is still less well investigated. Despite these weaknesses results of several clinical trials including several hundreds of patients with ischemic heart disease have been published. However, there are no solid data showing that any of these approaches can regenerate human myocardium. Even the effectiveness of cell therapy in these approaches is doubtful. In future we need in this important field of regenerative medicine: i) more experimental data in large animals that are closer to the anatomy and physiology of humans, including data on dose effects, comparison of different cell types and different delivery routes; ii) a better understanding of the molecular mechanisms involved in the fate of transplanted cells; iii) more intensive research on genuine regenerative medicine, applying genetic regulation and cell engineering.

Keywords: stem cells, cardiovascular disease

Introduction

In some vertebrates such as zebrafish and newts cardiac regeneration was documented after severe injury based on division of cardiomyocytes. However, there is not yet proof-of-concept that stem cells can regenerate substantially damaged hearts in humans. Reviewing the literature on the clinical utility of human stem cells in cardiovascular diseases demands controversial considerations. First, clinicians have started studies on bone marrow-derived mononuclear cells (BMC) and myoblasts. Second, clinicians have obviously been influenced by publications in 2001 demonstrating that BMC can repair rodent hearts after experimental myocardial infarction. Neither the intramyocardial injection technique nor the cell type used in these preclinical studies was employed in the first clinical study on BMC therapy in humans with myocardial infarction. Furthermore although the paper was entitled “Repair of infarcted myocardium”, the study was a non-randomized feasibility and safety study, and naturally the data could not provide any evidence for anatomical repair or regeneration influenced by the injected cells. Research on clinical use of stem cell therapy in cardiology was started with inadequate study design and misleading terms and definitions. Many questions have been raised on the validity of stem cell therapy research in cardiology. Even the proof-of-concept of regeneration of damaged hearts...
is highly controversial, since transdifferentiation of BMC into myocytes\textsuperscript{3,4} could not be reproduced by other groups, and transfusion of myocytes with labeled BMC has been demonstrated, raising the question of misinterpretation of cell transdifferentiation reports.\textsuperscript{6,7} Scientific progress in cell therapy or regenerative medicine is therefore in danger of being delayed. Do basic researchers and clinicians make the wrong studies? It is questionable that the first clinical trials on cell therapy in cardiology started without exact translation of large animal experiments.\textsuperscript{5,8} It would be not the first time that an important therapeutic approach in medical science has been delayed in the beginning, because clinical utility has been demanded too eagerly, as occurred, for example, in the first bone marrow transplantation, trials of gene therapy, and the first human heart transplantation.

In the large field of tissue engineering including heart valve engineering, artificial myocardial tissue, and engineered heart tissue, which so far are based mostly on neonatal rat cardiomyocytes, we like to refer on reviews focusing on this important preclinical work.\textsuperscript{9,10}

**Embryonic stem cells**

In 1998 human embryonic stem cells (hESC) were first isolated.\textsuperscript{11} These cells have the capacity for unlimited growth and per se transdifferentiation to most of all types of body cells. Mouse ESC had been isolated 17 years before however, there is still no proof that implantation of ESC in humans can cure a single chronic disease.\textsuperscript{12} Despite the controversial interests between religious and political groups there is also concern for scientific reasons. Immunological reactions and the capability of forming teratomas after injection of undifferentiated ESC into the heart have been described.\textsuperscript{9,13–15} Although others have not observed these findings, and there is no obvious reason why these experiments did not show teratomas, it would be irresponsible to use undifferentiated ESC in humans. On the other hand, genetic selection of ESC as applied by the Field’s group\textsuperscript{16} is capable of creating ES-derived myocytes that have been successfully engrafted in the host heart. Engrafting of these ESCs was documented by immunostaining and alignment and apposition with host myocardial cells. Zandstra et al\textsuperscript{17} selected myosin + cardiomyocytes out of mouse ESC before transfecting with a fusion gene consisting of cardiac myosin and neomycin resistance genes and neomycin treatment afterwards. Retinoic acid seemed to promote cardiac differentiation. Other genetic selection methods include fluorescent protein expression driven by different cardiac promotors.\textsuperscript{15,18–20} Also, other groups showed improvement of left ventricular ejection fraction by echocardiography after mouse ESC implementation.\textsuperscript{21–23} Engineered ESC has not been shown to form teratomas in these reports.

**Induced pluripotent stem cells (iPS)**

Most recently, adult human somatic cells were reprogrammed to pluripotent stem cells by transduction of four transcription factors: Oct3/4, Sox2,Klf4, and c-Myc.\textsuperscript{24} This raises great hope for future regenerative therapy.\textsuperscript{25} Thus, the problems of immunological rejection and embryo destruction can be overcome. The era of real cell replacement therapy could start with the onset of clinical trials after basic researchers and clinicians take account of the lessons learned from cell therapy trials performed. The successful establishment of multipotent adult germline stem cells (maGSCs) from mouse testis has opened another interesting route for true regenerative medicine in cardiovascular diseases. These authors found that maGSCs transplanted into normal hearts of mice were able to proliferate and differentiate. No tumor formation was detected up to 1 month after cell transplantation in these experiments.\textsuperscript{26,27}

Cell cycle activity reinduction in cardiomyocytes could be another promising approach.\textsuperscript{28,29}

**Bone marrow-derived cells**

Starting with the pioneer works of Kocher et al and Orlic et al,\textsuperscript{3,4} since 2001 intramyocardial delivery of bone marrow-derived cells have been shown to improve left ventricular function in the ischemically damaged heart.\textsuperscript{30} Several clinical reports indicate the benefit of bone marrow-derived cells (BMC) grafting in patients with acute myocardial infarction (AMI), including CD133+ and CD34+.\textsuperscript{30–37} Bone marrow-derived mononuclear stem cells (BMC) and mesenchymal stem cells. Recent reports on intracoronary application of BMC in humans exhibit controversial results with regard to the improvement of left ventricular function (LVEF). Whereas the TOPCARE-AMI, REPAIR and IACT studies, and others revealed an increase in LVEF\textsuperscript{37–40} (approx. 3% increase of LVEF) the studies by Janssens et al\textsuperscript{41} and Lunde\textsuperscript{42} et al could not reproduce the results.

However, it is difficult to compare the results, because most groups that detected an improvement of LVEF in the cell groups showed impairment of LVEF in the control groups and vice versa. In the BOOST trial the placebo group even increased the LVEF more than the cell group after 18 months. Moreover, different imaging methods (MRI, left ventricular angiography, echocardiography) were applied in the different studies. The date of cell injection in patients after acute myocardial infarction ranged from 3 to 12 days, which makes a huge difference, since the stunning phase after
revascularization takes place particularly during that time and discrimination between cell effects and discontinuation of the stunning phenomenon is impossible.

Moreover, the clinical studies are not comparable to each other, because different cell types, different isolation and selection techniques, different injection techniques, and different time intervals of cell administration after myocardial infarction are applied in the study protocols. Nonetheless, a meta-analysis of 10 controlled trials enrolling 698 patients after acute myocardial infarction treated with BMC suggest a short-term improvement of LVEF (2.97%).

Another problem is the shortening of telomeres of BMC which is responsible for decreased replicative capacity. This phenomenon is also described in endothelial progenitor cells. Moreover, risk factors for cardiovascular diseases correlate with higher rated of in vitro senescence. This was also observed for cardiac stem cells.

Mesenchymal Stem Cells (MSC)

MSC were discovered and described as bone marrow stromal cells with multipotent potential. Cloned MSCs can differentiate into osteoblasts, adipocytes and chondrocytes. Even cardiomyocytes were generated from MSC in vitro by demethylation with 5-azacytidine. Most studies used undifferentiated MCSs for injection in the damaged heart without differentiation into cardiomyocytes and lack of electromechanical junctions with host cells. But attenuation of pathological left ventricular remodeling was observed frequently. This is in accordance with other studies using allogeneic MSC. Moreover, MSC are described to induce tolerance which could be responsible for the reduction of graft-versus-host disease, rejection, and modulation of inflammation. These results make MSC interesting cell types for future research, especially for pharmaceutical companies, eg, Osiris Therapeutics.

New ongoing trials like the C-CURE (Cardio3 Biosciences) trial will show new results of intramyocardial delivery of MSC in different dosages in chronic ischemic heart disease. But certainly they will also raise questions about the fate and effectiveness of autologous MSCs.

CD133+ progenitor cells

CD133+ progenitor cells are examples for further cell therapy approaches. They can be extracted from the bone marrow and from peripheral blood after leukapheresis and have been shown to contribute to neoangiogenesis. These progenitor cells seem to have similar positive effects on LVEF as BMC in clinical pilot trials and were used with very few preclinical experimental investigations before. Large animal experiments are still lacking.

Myoblasts

Mouse skeletal muscle have been shown to contain a population of precursor cells that can differentiate into beating cells that express cardiomyocyte features. In humans satellite cells (myoblasts) have been identified which can differentiate into myotubes and improve left ventricular function in animal experiments. But there is no evidence that these cells can differentiate into cardiomyocytes.

Despite early research on skeletal myoblasts injection in the injured heart there are several publications that showed that myoblasts can induce proarrhythmogenic effects and are therefore less suitable for clinical trials (paragraph stem cells and arrhythmogeneity). Intramyocardial myoblast injection therapy studies in patients with ischemic cardiomyopathy have been performed mostly during bypass surgery. These trials were conducted with simultaneous coronary reperfusion, so that precise discrimination of the cell injection effect and reperfusion therapy is problematic. This MAGIC trial was stopped because of lack of efficacy.

Adipose derived stem cells

Adipocyte-derived stem cells are multilineage cells within the stroma vascular fraction of subcutaneous adipose tissue. These cells express surface markers Sca-1 and CD44, but not CD34,CD31, c-kit and CD45. They have angiogenic potential by secreting of VEGF and HGF. Even cardiomyocyte-like transdifferentiation, in vitro expansion and cardioprotective effects in a mouse-infarction model has been decribed.

Resident myocardial progenitor cells

Recently, the myocardium – formerly known as a postmitotic tissue – was shown to contain cells with regenerative capacity like other tissues, eg, the skin, bone marrow, intestine. These cardiac stem cells show a reentry into the cell cycle, are clonogenic, self-renewing and multipotent and capable to regenerate the ischemic myocardium after injection into the border zone of myocardial infarction. Only a small number of these cells are distributed in the atria, the ventricles, and the epicardium. Although, resident cardiac stem cells have been shown to have the potential to differentiate into cardiomyocytes, endothelial, and smooth muscle cells, this occurs at a very low rate. However, these cardiac stem cells could be isolated and amplified in vitro and therefore are interesting
candidates for induction of myocardial regeneration.\textsuperscript{46,73–76} Recently, evidence of renewal of human cardiomyocytes (1\% annually at the age of 25) was suggested by analysis of carbon-14 integration in human cardiomyocyte DNA, but whether this renewal derives from residential stem cells or cardiomyocyte duplication is not clear.\textsuperscript{77}

**Paracrine effects of stem cells**

Recently some experimental data have confirmed paracrine effects of stem cells, including angiogenesis and antiapoptotic effects.\textsuperscript{78–81} Particularly MSC were investigated and some studies provide evidence for this hypothesis.\textsuperscript{80,81} Dai et al\textsuperscript{82} and Tang et al\textsuperscript{83} reported on the enhanced expression of bFGF, SDF1-alpha, and vascular endothelial growth factor (VEGF) accompanied by a downregulation of proapoptotic protein Bax in ischemic myocardium after MSC implantation. Cultured MSC were shown to secret large amounts of angiogenic, antiapoptotic, hepatocyte growth factor and insulin-like growth factor-1.\textsuperscript{82} It seems that the beneficial effects of MSC are mediated by inhibition of myocardial fibrosis and an increase of angiogenesis and not by transdifferentiation.

Paracrine effects of myoblasts have also been described more recently.\textsuperscript{83} These effects include proangiogenic (PDF), anti-apoptotic (BAG-1, BCL-2) and extracellular matrix remodeling (MMP-2, MMP-7) genes.

It can be assumed that paracrine and angiogenic effects are responsible for the cardioprotective effects on heart function as described in other studies.\textsuperscript{55,79,80,84,85}

However, the term “regenerative medicine”, if applied specifically to stem cell engraftment and forming new differentiated myocytes, would then be misleading.

**Stem cells and arrhythmogenicity**

Safety concerns on the injection of skeletal myoblasts in the chronic ischemic myocardium in clinical studies were raised after documentation of ventricular tachycardias.\textsuperscript{8,86} With regard to the implantation of myoblasts in clinical studies, most ventricular arrhythmic events occurred in the first 4 weeks after cell implantation. In 4 out of 10 patients, ventricular tachycardias occurred between 11 and 22 days;\textsuperscript{8} in similar studies 2 patients out of 21 developed ventricular tachycardias 1 day after coronary artery bypass surgery.\textsuperscript{64,87}

Mechanisms of arrhythmia include re-entry, ectopy, and automaticity and potentially the heterogeneity of action potentials of implanted cells. Particularly, implantation of myoblasts has been shown to create an arrhythmogenic substrate, because the implanted cells do not build junctions to the surrounding myocytes.\textsuperscript{88} In these studies myoblasts labeled with Green fluorescent protein were transplanted into rat infarcted myocardium, and differentiated into peculiar “hyperexcitable myotubes with a contractile activity fully independent of neighbouring cardiomyocytes”\textsuperscript{89} or were located in cell clusters without connexin expression.\textsuperscript{89} Unfortunately, this analysis was published after performance of clinical trials.

Arrhythmogenicity can be induced through re-entry, automaticity, or triggered activity. All these phenomena can be investigated in large animal models, but publications on this topic in these models are rare.

Only few studies have addressed the electrophysiological properties of transplanted mesenchymal stem cells (MSC), although at present these cells are being studied in several cardiological clinical studies.\textsuperscript{90}

Some authors have described that mixtures of MSC and neonatal rat cardiomyocytes exhibit an arrhythmogenic substrate with decreased conduction velocity and easily inducible sustained re-entrant tachycardia, suggesting a proarrhythmic substrate induced by MSC.\textsuperscript{91,92} Chen et al reported that MSC prolonged local activation time and increase the activation time dispersion in a rabbit heart failure model.\textsuperscript{93} Thus, the therapeutic potential of mesenchymal stem cells for myocardial regeneration may be limited by proarrhythmic effects. Moreover, MSC have been described to alter electrophysiological properties in a large animal model.\textsuperscript{94} The authors described a significantly shorter epicardial effective refractory period at all pacing sites 3 months after pigs received MSC intravenously, suggesting a proarrhythmic potential.

Our group evaluated the electrophysiological effects of intramyocardial MSC injection based on a three-dimensional electromechanical mapping technique \textit{in vivo}. We found no change in conduction velocity and no evidence of a substrate modification towards a higher risk for re-entry tachycardias in the area of injected cells in a post-infarction porcine model.\textsuperscript{51} The results of the study by Mills et al revealed that intravenous MSC infusion (contrary to our study using intramyocardial injection) in a rat acute infarction model even tended to reduce arrhythmia inducibility.\textsuperscript{95} In that study MSC enhanced electrical viability and preserved impulse propagation in the infarct border zone as demonstrated by an optical mapping system. Histologically MSC shows a diffuse engraftment in the host myocardium and expressed connexin.

In clinical studies implanting BMC intramyocardially in patients with chronic ischemic heart disease the incidence of ventricular arrhythmia do not increase. These clinical studies were performed using the NOGA mapping system in patients with myocardial ischemia and no revascularisation option.\textsuperscript{96–98}
showing improvement of regional wall motion and perfusion, and partly of ejection fraction. In the study by Perin et al, 1 patient died 14 weeks after BMC implantation, presumably of sudden cardiac death. In 20 patients treated with BMC Beeres et al could not find an increased incidence of ventricular arrhythmias in holter monitoring. Corresponding to our preclinical results, BMC did not alter electrophysiological properties evaluated with electromechanical mapping before and 3 months after cell injection. Programmed ventricular stimulation was performed only in 1 randomized clinical study which found no differences between the BMC group and the control group. This study included intracoronary infusion in patients with acute myocardial infarction. In clinical studies infusing BMC, no proarrhythmic effect has yet been described.

For the transplantation of ESC-derived myocytes, further studies should address the arrhythmogenic potential in large animal models. Zhang et al described an increase of arrhythmogenic potential of embryonic stem cell derived cardiomyocytes. These cardiomyocytes showed spontaneous activity, prolonged potential duration of action, and easily inducible arrhythmias, and therefore the arrhythmogenic potential should be carefully investigated.

**Cell delivery techniques**

Our group applied intramyocardial injection, because this is by far the most-used delivery technique in preclinical studies. Moreover we tested efficacy and safety in a large animal model (swine) before starting a trial in humans. It is remarkable that most investigators prefer the intracoronary route, despite the fact that very few animal studies exist on this technique, and most studies have used rodents with intramyocardial cell injections. It is not necessary to use a different delivery route in humans. A simple explanation might be the fact that experimental studies on intracoronary cell injection are expensive due to the need for large animals. In contrast, in humans intracoronary cell delivery is cheaper and less time consuming for interventional cardiologists, because no left ventricular mapping is needed as for intramyocardial cell injection. Moreover the intramyocardial cell delivery technique is more evident, since preclinical experiments using radiolabeled cells indicate that intracoronary infusion results in a myocardial cell residency of 2.6% compared with 11.0% using the intramyocardial injection approach. Therefore, intramyocardial injection may have a more pronounced effect on LV function. Furthermore, intracoronary cell injection was associated with an increased remote organ engraftment compared with the intramyocardial injection in both an animal model as well as a clinical study.

**Challenges and future directions**

The rapid translation of preclinical cell-based therapy to restore damaged myocardium has raised questions concerning the best cell type as well as the best delivery route, and the best time of cell injection into the myocardium. All these questions should be addressed and challenged by the Task Force of the European Society of Cardiology, especially as several new clinical trials are in progress in the United States, Europe and in Asia without standardization of methods (cell harvest, isolation, preparation, delivery, dosage). Pharmacokinetics and pharmacodynamics should be assessed in new drugs as well as in cell therapy. In a review by Murry et al it was pointed out that cell dosages ranged by 6700 fold in the published trials, which underline the need for standardization of cell products. Instead, the Task Force of the ESC stresses a “pragmatic approach to demonstrate clinical efficacy” and does not recommend testing all possible combinations of cell types, number of cells, and so on, in animal models, because it “would take the best part of the century”. Moreover, an extension to cardiomyopathy patients was demanded. In view of the controversies outlined in this review, these statements should be questioned.

Reviewing the literature on preclinical investigations, it is remarkable that nearly every cell type tested so far seems to be equipotent for positive effects on LV function independent of the timing after myocardial infarction, cell numbers and the methods used. Therefore, experimental models to directly compare different cell types should be evaluated to reduce investigator-related bias.

Most reports use rodent models not recognizing that there are major differences between rodents and large mammals in mechanisms of myocardial contraction and ischemia. Also, there is a wide spectrum of collateral flow between various mammalian species especially for the lack of pre-existing collaterals in the swine heart, but also from a metabolic standpoint in comparison with rodents. Most clinical studies do not adapt the protocols from experimental studies, making comparison with preclinical work difficult. Rodent hearts seem to be regenerative. However, the murine heart is more likely to regenerate with a billion cells than a human heart weighing approximately 300 to 500 g. Certainly less than 5 g of heart tissue would be regenerated with these cell counts applied in clinical studies. None of the clinically used imaging techniques available are sensitive enough to detect the anatomical and functional contribution of 5 g of myocardial tissue, even if all cell survived, nested and transdifferentiated. Approximately 1 billion cells should transdifferentiate into cardiomyocytes and contract synchronously.
with host myocardium to restore ischemia-induced cardiac damage. Thus, even the possibility of self-renewing of the human heart is naturally limited to induce relevant effects in damaged hearts.

What we need for new clinical trials are

1. **biology**
   - What is the fate of injected cells in humans? Is there a long-term effect of injected cell in large animal experiments?
   - What dosage of cells is optimal in large animal experiments? Which cells are responsible for which biological effect? We need a better understanding of the molecular mechanisms involved in the fate of transplanted cells.

2. **technical evaluation**
   - What delivery route is most effective? What is the best point of time to deliver cells? What are the dose effects?
   - iii intensifying the research on new approaches for stem cell engineering and the research on genuine regenerative medicine applying genetic regulation.

**Disclosure**

KK has received educational honoraria from BDS, USA.

**References**


